Dose Escalation Methods in Phase I Cancer Clinical Trials

By C. Tourneau, J. Lee, L. Siu. Journal of the National Cancer Institute, 2009

829 citations recorded by the source corpus.

Phase I clinical trials are an essential step in the development of anticancer drugs. The main goal of these studies is to establish the recommended dose and/or schedule of new drugs or drug combinations for phase II trials. The guiding principle for dose escalation in phase I trials is to avoid exposing too many patients to subtherapeutic doses while preserving safety and maintaining rapid accrual. Here we review dose escalation methods for phase I trials, including the rule-based and model-based dose escalation methods that have been developed to evaluate new anticancer agents. Toxicity has traditionally been the primary endpoint for phase I trials involving cytotoxic agents. However, with the emergence of molecularly targeted anticancer agents, potential alternative endpoints to delineate optimal biological activity, such as plasma drug concentration and target inhibition in tumor or surrogate tissues, have been proposed along with new trial designs. We also describe specific methods for drug combinations as well as methods that use a time-to-event endpoint or both toxicity and efficacy as endpoints. Finally, we present the advantages and drawbacks of the various dose escalation methods and discuss specific applications of the methods in developmental oncotherapeutics.

Subfields: Cancer Research, Management Science and Operations Research, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/2e565a213a4cc812f4610beb8f52eaa028d8bf12

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

  1. Robert Langer
  2. V. Préat
  3. F. Danhier

Citations in the corpus